SanBio Company Limited (TYO: 4592)

Japan flag Japan · Delayed Price · Currency is JPY
1,020.00
-19.00 (-1.83%)
Nov 15, 2024, 3:45 PM JST
119.83%
Market Cap 64.99B
Revenue (ttm) n/a
Net Income (ttm) -2.17B
Shares Out 68.63M
EPS (ttm) -32.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 596,300
Open 1,035.00
Previous Close 1,039.00
Day's Range 1,009.00 - 1,035.00
52-Week Range 380.00 - 1,489.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Dec 16, 2024

About SanBio Company

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 29
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4592
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.